Theravance Biopharma (TBPH) Receivables (2013 - 2019)

Theravance Biopharma (TBPH) has 7 years of Receivables data on file, last reported at $20.1 million in Q3 2019.

• On a quarterly basis, Receivables rose 189.81% year-over-year to $20.1 million in Q3 2019; TTM through Sep 2019 was $20.1 million, a 189.81% increase from a year earlier, with the FY2018 full-year figure at $10.7 million, up 14.0% from the prior year.
• Receivables for Q3 2019 stood at $20.1 million, roughly flat from $20.1 million in the prior quarter.
• Over the last five years, Receivables for TBPH reached as high as $39.1 million in Q1 2016 and fell as low as $1.9 million in Q4 2015.
• Historically, Receivables has averaged $15.5 million across 5 years, with a median of $10.7 million in 2018.
• Across the five-year window, Receivables soared 28479.35% in 2015 and sank 81.96% in 2017, its largest moves.
• Year by year, Receivables stood at $1.9 million in 2015, then jumped by 405.83% to $9.7 million in 2016, then fell by 3.7% to $9.4 million in 2017, then rose by 14.0% to $10.7 million in 2018, then jumped by 88.2% to $20.1 million in 2019.
• Per Business Quant data, the three most recent Receivables figures were $20.1 million in Q3 2019, $20.1 million in Q2 2019, and $7.9 million in Q1 2019.